Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (NASDAQ:JAGX) announced that its subsidiary Napo Pharmaceuticals sponsored an episode of The Gayly Dose podcast on World AIDS Day to raise awareness about HIV-related diarrhea. Over half of people living with HIV suffer from chronic diarrhea, negatively impacting their quality of life. The episode featured Jeremiah Robinson, an HIV Specialist, discussing Mytesi (crofelemer), the FDA-approved antidiarrheal treatment for HIV/AIDS patients. Mytesi is a plant-based drug that alleviates symptoms and supports overall well-being.

Jaguar Health reported approximately $3.1 million in prescription product net revenue for Q3 2022, marking an 8.2% increase from Q2 2022 and a substantial 412% rise from Q3 2021. The growth is attributed to the successful transition to a limited distribution network of specialty pharmacies, reducing distribution costs and enhancing net pricing. Noteworthy upcoming events include the completion of patient enrollment for a Phase 3 trial of crofelemer for cancer therapy-related diarrhea expected in Q2 2023. Jaguar also received Orphan Drug Designation for crofelemer in Europe for Microvillus Inclusion Disease.

Jaguar Health, Inc. (NASDAQ:JAGX) will host an investor webcast on November 14, 2022, at 8:30 AM ET to discuss its third-quarter financial results and corporate updates. Registration for participation is available via the provided link. The company specializes in developing plant-based prescription medications for gastrointestinal issues in humans and animals. Notably, its crofelemer drug candidate is undergoing a pivotal Phase 3 clinical trial aimed at cancer patients.

Jaguar Health (NASDAQ:JAGX) announced sponsorship of the dvm360 Live! episode on October 26, 2022, to promote Canalevia-CA1, the first FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs. The initiative aims to raise awareness and encourage veterinary clinics to contribute to the Take C.H.A.R.G.E. registry, tracking canine cancer data. This registry is the first of its kind in the U.S., providing essential insights for better diagnosis and treatment of canine cancer. Canalevia-CA1 offers a solution to a significant unmet need in veterinary oncology.

Jaguar Health, Inc. (NASDAQ:JAGX) announced the publication of the HALT-D trial results in the journal Breast Cancer Research and Treatment. The study evaluated crofelemer, a plant-based antidiarrheal, for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients. CID affects up to 80% of these patients, leading to hospitalization in some cases. While crofelemer is currently in a Phase 3 trial for adult patients with solid tumors, the HALT-D trial results are significant for addressing CID, a debilitating side effect of cancer treatments.

Jaguar Health has received Orphan Drug Designation (ODD) for crofelemer to treat Microvillus Inclusion Disease (MVID) in the EU. This designation follows the earlier ODD granted for short bowel syndrome (SBS). The designation enhances the potential for expanded patient access to crofelemer in Europe, with expected clinical data presentations planned for December 2022. Additionally, Pravin Chaturvedi of Jaguar was honored at the Boston Biotechnology Summit for his contributions to the pharmaceutical industry.

Jaguar Health, under its Jaguar Animal Health tradename, is co-sponsoring the Closing Ceremony at the Veterinary Cancer Society Annual Conference on October 15, 2022. The event aims to promote the Take C.H.A.R.G.E. initiative, a national cancer registry for dogs, which tracks cancer incidence and prevalence. This free registry currently holds nearly 36,000 patient records and 830 confirmed diagnoses, providing valuable data to veterinarians. Additionally, Jaguar is showcasing its FDA conditionally approved product, Canalevia-CA1, for treating chemotherapy-induced diarrhea in dogs.

Jaguar Health (NASDAQ:JAGX) announced that all four proposals were approved at its 2022 Special Meeting of Stockholders held on September 30, 2022. Detailed information about these proposals can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 29, 2022. The Company focuses on developing plant-based, non-opioid medicines for gastrointestinal distress in humans and animals. Jaguar Health is also engaged in ongoing clinical trials for its crofelemer drug product.

Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), has received FDA activation for its Investigational New Drug (IND) application for NP-300, aimed at treating moderate-to-severe diarrhea due to cholera and other pathogens. This approval positions Napo to initiate a phase I clinical trial, following which it can progress to the next stages of development. NP-300, derived from Croton lechleri, could qualify for a Tropical Disease Priority Review Voucher, potentially yielding significant revenue upon approval. Cholera impacts millions globally, highlighting the drug's importance.